Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer

doi:10.4251/wjgo.v16.i6.2429

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (391)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

289

Figures (1-1)

Tables (1-4)

Sum=351

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=32

Jun 15, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2429-2438
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2429

Table 1 Clinical characteristics of the colorectal cancer patients

Variables	DFS	Non-DFS	P value
n	451	62
Male, (%)	61.20	62.90	0.890
Age, yr	66.65 ± 11.08	68.48 ± 10.87	0.221
Diabetes mellitus (%)	10.86	12.90	0.666
Hypertension (%)	31.49	30.65	1.000
Smoking history¹ (%)	20.40	30.65	0.072
Alcohol intake history² (%)	11.87	20.97	0.068
Family history of CRC (%)	4.88	4.84	1.000
NAFLD (%)	21.51	29.03	0.195
BMI, kg/m²	23.33 ± 3.22	23.59 ± 2.55	0.538

¹Smoking history was defined in our study as regular daily inhalation of cigarettes that lasted at least until surgery without cessation.

²Alcohol consumption was defined as an average daily intake of ethanol greater than or equal to 30 grams per day (about two drinks a day) without abstinence.

CRC: Colorectal cancer; NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; DFS: Disease-free survival.

Table 2 Univariate Cox regression analysis of disease-free survival

Variables	BE	SE	Wald	P value	HR (95%CI)
Male, (%)	0.179	0.276	0.420	0.517	1.196 (0.696-2.055)
Age, yr	-.005	0.012	0.169	0.681	0.995 (0.972-1.018)
BMI, kg/m²	0.026	0.041	0.413	0.520	1.027 (0.947-1.113)
Diabetes mellitus (%)	-0.284	0.468	0.369	0.544	0.753 (0.301-1.883)
Hypertension (%)	-0.133	0.257	0.269	0.604	0.875 (0.529-1.447)
Smoking history (%)	0.610	0.280	4.751	0.029	1.840 (1.063-3.185)
Alcohol intake history (%)	0.590	0.324	3.315	0.069	1.805 (0.956-3.407)
Family history of CRC (%)	0.435	0.518	0.705	0.401	1.545 (0.560-4.266)
NAFLD (%)	0.393	0.288	1.857	0.173	1.482 (0.842-2.608)
WBC, 10⁹/L	-0.027	0.077	0.122	0.727	0.974 (0.837-1.132)
LY, 10⁹/L	0.035	0.210	0.028	0.868	1.036 (0.686-1.564)
MO, 10⁹/L	-0.164	0.841	0.038	0.846	0.849 (0.163-4.413)
NEUT, 10⁹/L	-0.037	0.090	0.167	0.683	0.964 (0.808-1.150)
Hb, g/L	0.005	0.006	0.727	0.394	1.005 (0.993-1.017)
PLT, 10⁹/L	-0.005	0.002	5.957	0.015	0.995 (0.991-0.999)
T-BIL, μmol/L	0.006	0.025	0.066	0.798	1.007 (0.958-1.058)
D-BIL, μmol/L	-0.010	0.086	0.013	0.908	0.990 (0.836-1.172)
TP, g/L	0.002	0.021	0.012	0.913	1.002 (0.961-1.045)
ALB, g/L	-0.014	0.030	0.216	0.642	0.986 (0.931-1.045)
GLB, g/L	0.018	0.029	0.389	0.533	1.018 (0.962-1.078)
ALT, U/L	-0.002	0.008	0.036	0.849	0.998 (0.983-1.015)
AST, U/L	-0.016	0.019	0.637	0.425	0.985 (0.948-1.023)
TBA, μmol/L	0.000	0.023	0.000	0.990	1.000 (0.956-1.047)
PA, mg/L	0.002	0.002	0.857	0.355	1.002 (0.998-1.006)
UREA, mmol/L	-0.001	0.088	0.000	0.990	0.999 (0.841-1.186)
FBG, mmol/L	0.119	0.072	2.742	0.098	1.126 (0.978-1.297)
Cr, μmol/L	0.002	0.008	0.072	0.789	1.002 (0.986-1.019)
UA, mmol/L	-0.392	1.119	0.123	0.726	0.675 (0.075-6.055)
HbA1c, %	0.017	0.156	0.011	0.915	1.017 (0.749-1.380)
CEA, ng/mL	0.004	0.004	1.067	0.302	1.004 (0.996-1.013)
CA19-9, U/mL	0.000	0.001	0.071	0.789	1.000 (0.998-1.001)
TC, mmol/L	0.144	0.179	0.648	0.421	1.155 (0.813-1.639)
TG, mmol/L	0.216	0.232	0.868	0.351	1.241 (0.788-1.955)
HDL-C, mmol/L	-0.054	0.501	0.012	0.914	0.948 (0.355-2.529)
LDL-C, mmol/L	0.142	0.223	0.405	0.525	1.152 (0.744-1.784)
Apo-A1, g/L	-0.788	0.803	0.964	0.326	0.455 (0.094-2.194)
Apo-B, g/L	0.707	1.075	0.432	0.511	2.027 (0.246-16.676)
LP-a, mg/dL	-0.001	0.012	0.005	0.944	0.999 (0.977-1.022)

CRC: Colorectal cancer; NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; WBC: White blood cell; LY: Lymphocyte; MO: Monocyte; NEUT: Neutrophil; Hb: Hemoglobin; PLT: Blood platelet count; T-BIL: Total bilirubin; D-BIL: Direct bilirubin; TP: Total protein; ALB: Albumin; GLB: Globulin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBA: Total bile acid; PA: Prealbumin; UREA: Urea nitrogen; FBG: Fasting blood glucose; Cr: Creatinine; UA: Uric acid; HbA1c: Glycosylated hemoglobin A1c; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; Apo-A1: Apolipoprotein A1; Apo-B: Apolipoprotein B; LP-a: Lipoprotein A; HR: Hazard ratio; CI: Confidence interval.

Table 3 Univariate Cox regression analysis of overall survival

Variables	BE	SE	Wald	P value	HR (95%CI)
Male, (%)	-0.329	0.313	1.102	0.294	0.720 (0.390-1.330)
Age, yr	0.031	0.015	4.211	0.040	1.031 (1.001-1.062)
BMI, kg/m²	0.020	0.049	0.157	0.692	1.020 (0.926-1.123)
Diabetes mellitus (%)	0.098	0.477	0.042	0.838	1.102 (0.433-2.809)
Hypertension (%)	0.014	0.222	0.004	0.949	1.014 (0.656-1.568)
Smoking history (%)	0.418	0.343	1.482	0.223	1.519 (0.775-2.976)
Alcohol intake history (%)	0.492	0.394	1.558	0.212	1.635 (0.755-3.541)
Family history of CRC (%)	0.476	0.600	0.630	0.427	1.610 (0.497-5.215)
NAFLD (%)	0.614	0.329	3.471	0.062	1.847 (0.969-3.523)
WBC, 10⁹/L	-0.054	0.094	0.327	0.568	0.948 (0.789-1.139)
LY, 10⁹/L	0.074	0.249	0.089	0.765	1.077 (0.662-1.754)
MO, 10⁹/L	-1.432	1.110	1.663	0.197	0.239 (0.027-2.105)
NEUT, 10⁹/L	-0.074	0.112	0.434	0.510	0.929 (0.746-1.156)
Hb, g/L	-0.003	0.007	0.149	0.700	0.997 (0.984-1.011)
PLT, 10⁹/L	-0.002	0.002	1.072	0.301	0.998 (0.993-1.002)
T-BIL, μmol/L	-0.070	0.038	3.484	0.062	0.932 (0.866-1.004)
D-BIL, μmol/L	-0.243	0.128	3.611	0.057	0.784 (0.610-1.008)
TP, g/L	-0.005	0.025	0.040	0.841	0.995 (0.946-1.046)
ALB, g/L	-0.056	0.034	2.643	0.104	0.946 (0.885-1.011)
GLB, g/L	0.045	0.033	1.788	0.181	1.046 (0.979-1.116)
ALT, U/L	-0.001	0.009	0.009	0.925	0.999 (0.981-1.017)
AST, U/L	-0.004	0.016	0.052	0.819	0.996 (0.966-1.028)
TBA, μmol/L	-0.009	0.031	0.089	0.765	0.991 (0.932-1.053)
PA, mg/L	0.000	0.003	0.001	0.978	1.000 (0.995-1.005)
UREA, mmol/L	0.022	0.104	0.045	0.832	1.022 (0.834-1.252)
FBG, mmol/L	0.122	0.082	2.242	0.134	1.130 (0.963-1.326)
Cr, μmol/L	-0.011	0.010	1.260	0.262	0.989 (0.969-1.009)
UA, mmol/L	-2.209	1.874	1.390	0.238	0.110 (0.003-4.321)
HbA1c, %	0.206	0.086	5.754	0.016	1.229 (1.038-1.455)
CEA, ng/mL	0.008	0.004	4.896	0.027	1.008 (1.001-1.016)
CA19-9, U/mL	-0.005	0.007	0.476	0.490	0.995 (0.981-1.009)
TC, mmol/L	0.431	0.206	4.350	0.037	1.538 (1.026-2.305)
TG, mmol/L	0.211	0.272	0.601	0.438	1.235 (0.724-2.107)
HDL-C, mmol/L	0.264	0.552	0.229	0.632	1.303 (0.441-3.846)
LDL-C, mmol/L	0.434	0.258	2.820	0.093	1.543 (0.930-2.559)
Apo-A1, g/L	0.848	0.832	1.038	0.308	2.335 (0.457-11.931)
Apo-B, g/L	1.200	1.216	0.974	0.324	3.320 (0.306-35.966)
LP-a, mg/dL	0.006	0.011	0.253	0.615	1.006 (0.983-1.029)

Table 4 Multivariate Cox regression analysis of overall survival

Variables	BE	SE	Wald	P value	HR (95%CI)
CEA, ng/mL	0.019	0.005	16.075	< 0.001	1.019 (1.010-1.029)
TC, mmol/L	0.006	0.011	0.253	0.615	1.006 (0.983-1.029)

CEA: Carcinoembryonic antigen; TC: Total cholesterol; TG: Triglyceride; HR: Hazard ratio; CI: Confidence interval.

Citation: Jing PF, Chen J, Yu ED, Miao CY. Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer. World J Gastrointest Oncol 2024; 16(6): 2429-2438
URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2429.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i6.2429